08:47 AM EST, 11/21/2025 (MT Newswires) -- Esperion Therapeutics ( ESPR ) said Friday that its Japan partner Otsuka Pharmaceutical has received the National Health Insurance Price Listing and rolled out Nexletol tablets in the country to treat hypercholesterolemia and familial hypercholesterolemia.

Under the terms, Esperion will get $90 million total payment, and it is also entitled to receive additional sales milestone payments on net sales by Otsuka in Japan, the company said.

Shares of Esperion were up 2% in recent Friday premarket activity.